FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3094008052> ?p ?o ?g. }

• W3094008052 endingPage "e393" @default.
• W3094008052 startingPage "e382" @default.
• W3094008052 abstract "Abstract Background In this phase II clinical trial, we evaluated the efficacy of the nonanthracycline combination of carboplatin and nab-paclitaxel in early stage triple-negative breast cancer (TNBC). Patients and Methods Patients with newly diagnosed stage II–III TNBC (n = 69) were treated with neoadjuvant carboplatin (area under the curve 6) every 28 days for four cycles plus nab-paclitaxel (100 mg/m2) weekly for 16 weeks. Pathological complete response (pCR) and residual cancer burden (RCB) were analyzed with germline mutation status, tumor-infiltrating lymphocytes (TILs), TNBC molecular subtype, and GeparSixto immune signature (GSIS). Results Sixty-seven patients were evaluable for safety and response. Fifty-three (79%) patients experienced grade 3/4 adverse events, including grade 3 anemia (43%), neutropenia (39%), leukopenia (15%), thrombocytopenia (12%), fatigue (7%), peripheral neuropathy (7%), neutropenia (16%), and leukopenia (1%). Twenty-four patients (35%) had at least one dose delay, and 50 patients (72%) required dose reduction. Sixty-three (94%) patients completed scheduled treatment. The responses were as follows: 32 of 67 patients (48%) had pCR (RCB 0), 10 of 67 (15%) had RCB I, 19 of 67 (28%) had RCB II, 5 of 67 (7%) had RCB III, and 1 of 67 (2%) progressed and had no surgery. Univariate analysis showed that immune-hot GSIS and DNA repair defect (DRD) were associated with higher pCR with odds ratios of 4.62 (p = .005) and 4.76 (p = .03), respectively, and with RCB 0/I versus RCB II/III with odds ratio 4.80 (p = .01). Immune-hot GSIS was highly correlated with DRD status (p = .03), TIL level (p &lt; .001), and TNBC molecular subtype (p &lt; .001). After adjusting for age, race, stage, and grade, GSIS remained associated with higher pCR and RCB class 0/I versus II/III with odds ratios 7.19 (95% confidence interval [CI], 2.01–25.68; p = .002) and 8.95 (95% CI, 2.09–38.23; p = .003), respectively. Conclusion The combination of carboplatin and nab-paclitaxel for early stage high-risk TNBC showed manageable toxicity and encouraging antitumor activity. Immune-hot GSIS is associated with higher pCR rate and RCB class 0/1. This study provides an additional rationale for using nonanthracycline platinum-based therapy for future neoadjuvant trials in early stage TNBCs. Clinical trial identification number: NCT01525966 Implications for Practice Platinum is an important neoadjuvant chemotherapy agent for treatment of early stage triple-negative breast cancer (TNBC). In this study, carboplatin and nab-paclitaxel were well tolerated and highly effective in TNBC, resulting in pathological complete response of 48%. In univariate and multivariate analyses adjusting for age, race, tumor stage and grade, “immune-hot” GeparSixto immune signature (GSIS) and DNA repair defect (DRD) were associated with higher pathological complete response (pCR) and residual cancer burden class 0/1. The association of immune-hot GSIS with higher pCR holds promise for de-escalating neoadjuvant chemotherapy for patients with early stage TNBC. Although GSIS is not routinely used in clinic, further development of this immune signature into a clinically applicable assay is indicated." @default.
• W3094008052 created "2020-10-29" @default.
• W3094008052 creator A5004500382 @default.
• W3094008052 creator A5005344580 @default.
• W3094008052 creator A5005473474 @default.
• W3094008052 creator A5011540763 @default.
• W3094008052 creator A5019170187 @default.
• W3094008052 creator A5023917993 @default.
• W3094008052 creator A5028867448 @default.
• W3094008052 creator A5029656375 @default.
• W3094008052 creator A5031678728 @default.
• W3094008052 creator A5041448171 @default.
• W3094008052 creator A5041831958 @default.
• W3094008052 creator A5042373823 @default.
• W3094008052 creator A5074603645 @default.
• W3094008052 creator A5077481880 @default.
• W3094008052 creator A5078024122 @default.
• W3094008052 creator A5079121091 @default.
• W3094008052 creator A5082432682 @default.
• W3094008052 creator A5082853715 @default.
• W3094008052 creator A5085471282 @default.
• W3094008052 creator A5087409546 @default.
• W3094008052 creator A5088491898 @default.
• W3094008052 creator A5088975304 @default.
• W3094008052 date "2020-11-08" @default.
• W3094008052 modified "2023-10-17" @default.
• W3094008052 title "Phase II Trial of Neoadjuvant Carboplatin and Nab-Paclitaxel in Patients with Triple-Negative Breast Cancer" @default.
• W3094008052 cites W1701849548 @default.
• W3094008052 cites W1759030281 @default.
• W3094008052 cites W1871202334 @default.
• W3094008052 cites W1989938935 @default.
• W3094008052 cites W2032968026 @default.
• W3094008052 cites W2043515643 @default.
• W3094008052 cites W2048295112 @default.
• W3094008052 cites W2075894019 @default.
• W3094008052 cites W2086064725 @default.
• W3094008052 cites W2094523134 @default.
• W3094008052 cites W2096145980 @default.
• W3094008052 cites W2096745115 @default.
• W3094008052 cites W2100766868 @default.
• W3094008052 cites W2110645520 @default.
• W3094008052 cites W2114505219 @default.
• W3094008052 cites W2118605519 @default.
• W3094008052 cites W2120059431 @default.
• W3094008052 cites W2120431466 @default.
• W3094008052 cites W2125885282 @default.
• W3094008052 cites W2128458647 @default.
• W3094008052 cites W2134539328 @default.
• W3094008052 cites W2134878729 @default.
• W3094008052 cites W2144536924 @default.
• W3094008052 cites W2147415463 @default.
• W3094008052 cites W2153017356 @default.
• W3094008052 cites W2153206149 @default.
• W3094008052 cites W2154109215 @default.
• W3094008052 cites W2157285286 @default.
• W3094008052 cites W2159274850 @default.
• W3094008052 cites W2159427817 @default.
• W3094008052 cites W2170602872 @default.
• W3094008052 cites W2264815585 @default.
• W3094008052 cites W2295085830 @default.
• W3094008052 cites W2434209561 @default.
• W3094008052 cites W2516614932 @default.
• W3094008052 cites W2560367415 @default.
• W3094008052 cites W2585697071 @default.
• W3094008052 cites W2623425472 @default.
• W3094008052 cites W2734897937 @default.
• W3094008052 cites W2740705517 @default.
• W3094008052 cites W2749861364 @default.
• W3094008052 cites W2751474182 @default.
• W3094008052 cites W2762643147 @default.
• W3094008052 cites W2771978163 @default.
• W3094008052 cites W2779333875 @default.
• W3094008052 cites W2779944044 @default.
• W3094008052 cites W2788106879 @default.
• W3094008052 cites W2793228705 @default.
• W3094008052 cites W2803428420 @default.
• W3094008052 cites W2805124128 @default.
• W3094008052 cites W2807507329 @default.
• W3094008052 cites W2895846919 @default.
• W3094008052 cites W2897422388 @default.
• W3094008052 cites W2897766608 @default.
• W3094008052 cites W2905037142 @default.
• W3094008052 cites W2909799373 @default.
• W3094008052 cites W2939662863 @default.
• W3094008052 cites W2944205198 @default.
• W3094008052 cites W2944623054 @default.
• W3094008052 cites W2946550606 @default.
• W3094008052 cites W2946912773 @default.
• W3094008052 cites W2946918907 @default.
• W3094008052 cites W2970401899 @default.
• W3094008052 cites W3005738019 @default.
• W3094008052 cites W3006930853 @default.
• W3094008052 cites W3008697231 @default.
• W3094008052 cites W4205664642 @default.
• W3094008052 cites W4252714226 @default.
• W3094008052 doi "https://doi.org/10.1002/onco.13574" @default.
• W3094008052 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7930424" @default.
• W3094008052 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33098195" @default.

• next